Caplin Point Laboratories files SEBI Takeover Regulations disclosure (Reg 31(4))
Caplin Point Laboratories Limited submitted a Regulation 31(4) disclosure to NSE on 16 June 2026. Regulation 31(4) requires disclosure by a target company when the acquirer crosses a 5% shareholding threshold or announces an open offer. The substance of this acquisition - including the buyer's identity, consideration, number of shares, and timeline - is not yet publicly detailed in accessible sources.
Why it mattersThe filing triggers mandatory regulatory transparency under SEBI's takeover code; counsel should obtain the full disclosure from the exchange or company to assess materiality, open offer obligations, and minority shareholder protections.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]
Sources
- NSE Archives - Caplin Point Laboratories SEBI Takeover Disclosure · official
- BSE corporate announcements · official
- NSE corporate announcements · official
- CCI combination orders · official
Related deals
- Anupam Rasayan India acquires controlling stake in Bliss GVS Pharma; Kanga & Co advises sellers28 Oct 2026
- Fortis Healthcare Limited: Press Release28 Oct 2026 · ₹277 Cr
- Fortis Healthcare Limited: Acquisition28 Oct 2026
- ThinkLaw advises Jagsonpal Pharma on acquiring Group Pharma's wellness portfolio27 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026
- Mankind Pharma Limited: Scheme of Arrangement26 Oct 2026